Detalhe da pesquisa
1.
PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
Gut
; 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38857989
2.
Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma.
Gastroenterology
; 164(1): 72-88.e18, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36108710
3.
Prospective study of computer-aided detection of colorectal adenomas in hospitalized patients.
Scand J Gastroenterol
; 58(10): 1194-1199, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37191195
4.
[Current Studies and Evidence in Cholangiocarcinoma]. / Aktuelle Studien und Evidenz zum Cholangiokarzinom.
Zentralbl Chir
; 147(4): 389-397, 2022 Aug.
Artigo
em Alemão
| MEDLINE | ID: mdl-35863357
5.
Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome.
United European Gastroenterol J
; 11(1): 92-102, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36441143
6.
Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: Experience from Four Tertiary Centers.
Cancers (Basel)
; 14(7)2022 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35406493
7.
13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Clin Transl Gastroenterol
; 13(10): e00529, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36087052